$173.79
0.12% day before yesterday
Nasdaq, Nov 01, 09:00 pm CET
ISIN
US09062X1037
Symbol
BIIB
Sector
Industry

Biogen Stock News

Negative
Seeking Alpha
3 days ago
Biogen reported its Q3 earnings yesterday, October 30. Revenue of $2.5bn was reported and non-GAAP EPS of $4.08. Growth was generally flat or declining for many key assets, with the performance of AD drug Leqembi especially underwhelming.
Neutral
GlobeNewsWire
4 days ago
-New testing method highlights link between protofibrils and biomarkers for neurodegeneration--Patient and caregiver perspectives on five-year treatment with lecanemab -- Utilization of blood biomarkers to predict brain amyloid accumulation in AHEAD study of preclinical AD-
Neutral
Seeking Alpha
4 days ago
Biogen Inc. (NASDAQ:BIIB ) Q3 2024 Earnings Call Transcript October 30, 2024 8:30 AM ET Company Participants Stephen Amato - Senior Director of IR Chris Viehbacher - President and CEO Priya Singhal - Head of Development Mike McDonnell - CFO Alisha Alaimo - Head & President of North America Conference Call Participants Brian Abrahams - RBC Capital Markets Phil Nadeau - TD Cowen Marc Goodman - Le...
Positive
Market Watch
4 days ago
“We continue to see momentum with ongoing product launches and we are increasingly excited about the potential of our pipeline,” the company's CEO said.
Positive
Reuters
4 days ago
Biogen raised annual profit forecast and beat third-quarter profit expectations on Wednesday, as its cost-cutting measures helped make up for falling sales of its multiple sclerosis medicines.
Positive
CNBC
4 days ago
Biogen reported third-quarter revenue and adjusted earnings that topped expectations. The company also raised its full-year profit guidance.
Neutral
GlobeNewsWire
4 days ago
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Biogen Inc. (NASDAQ: BIIB) on behalf of long-term stockholders following a class action complaint that was filed against Biogen on May 22, 2024 with a Class Period from February 3, 2022 to February 13, 2024. Our investigation con...
Neutral
GlobeNewsWire
5 days ago
CAMBRIDGE, Mass. and SAN DIEGO, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer's, rare neurological, and immunological diseases.
Show more news

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today